University of the Witwatersrand   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Johannesburg South Africa (1896)

Organization Overview

First Clinical Trial
2004
NCT00080119
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Chris Hani Baragwanath Hospital | Clinical HIV Research Unit, University of the Witwatersrand | Ezintsha, a subdivision of Wits Reproductive Health and HIV Institute (Wits RHI) | Ezintsha, Faculty of Health Sciences University of the Witwatersrand | Harriet Shezi Children's Clinic, Chris Hani Baragwanth Hospital, WHI, University of the Witwatersrand | Jeffrey Kotzen | Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital | Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand | Perinatal HIV Research Unit of the University of the Witswatersrand | Perinatal HIV Research Unit of the University of the Witwatersrand | Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Hospital | Perinatal HIV Research Unit, University of Witwatersrand | RHRU National Office, University of Witwatersand, Johannesburg | Senior Radiation Oncologist | Shabir Madhi | Student - PhD Candidate | Univeristy of the Witwatersrand | University of the Witwatersrand. Themba Lethu Clinic. | University of the Witwatersrand, Thembaletu Clinic, Helen Joseph Hospital | University of Witwatersrand | University of Witwatersrand, South Africa | University of Witwatetersrand & Charlotte Maxek Johannestburg Academic Hospital | University or Witswatersrand | VPD- RMPRU | Willem Daniel Francois Venter | Wits Reproductive Health & HIV Institute, University of the Witswatersrand

Active Ingredients

Drugs in Phase 4 Trials (20)

adacel (1 trial)

attenuated measles vaccine (rubeovax) (1 trial)

azd1222 (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

fentanyl (Innovar) (1 trial)

hepatitis a vaccine, inactivated (vaqta) (1 trial)

inactivated influenza vaccine (7 trials)

inactivated varicella vaccine (1 trial)

indomethacin (indocin) (1 trial)

lamivudine (epivir) (8 trials)

levobupivacaine (chirocaine) (1 trial)

lopinavir (Kaletra) (8 trials)

morphine (1 trial)

mutagrip (1 trial)

nevirapine (viramune) (5 trials)

norgestrel (Ovral) (1 trial)

ritonavir (Norvir) (7 trials)

stavudine (zerit) (5 trials)

tenofovir (viread) (7 trials)

zidovudine (retrovir) (3 trials)

Drugs in Phase 3 Trials (31)

abacavir (ziagen) (2 trials)

bactrim (1 trial)

bedaquiline (sirturo) (1 trial)

bivalent subtype c gp120 (1 trial)

chlorhexidine (hibitane) (1 trial)

cisplatin (platinol) (1 trial)

clofazimine (lamprene) (1 trial)

darunavir (prezista) (1 trial)

delamanid (1 trial)

didanosine (videx) (1 trial)

dolutegravir (tivicay) (1 trial)

doravirine (pifeltro) (2 trials)

efavirenz (sustiva) (4 trials)

eidd-2801 (1 trial)

ethambutol (myambutol) (2 trials)

hydroxychloroquine (plaquenil) (1 trial)

inclisiran (1 trial)

isoniazid (nydrazid) (4 trials)

levofloxacin (levaquin) (1 trial)

linezolid (zyvox) (1 trial)

multi-valent pneumococcal conjugate vaccine (1 trial)

nitazoxanide (alinia) (2 trials)

platelet rich plasma (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

povidone-iodine (1 trial)

pyrazinamide (Aldinamide) (2 trials)

riamilovir (1 trial)

supraene (2 trials)

tenofovir alafenamide (genvoya) (2 trials)

thrombin (bovine) (Thrombostat) (1 trial)

vcp2438 (1 trial)

Drugs in Phase 2 Trials (16)

acetylsalicylic acid (aspirin) (1 trial)

acrivastine (Semprex-D) (1 trial)

aip-303 (1 trial)

chadox1 n-cov vaccine (1 trial)

daclatasvir (daklinza) (1 trial)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

ibuprofen (motrin) (1 trial)

matrix-m1 (1 trial)

mrkad5 hiv-1 gag/pol/nef (1 trial)

pravastatin (pravachol) (1 trial)

pseudoephedrine (Benylin) (1 trial)

pyridoxine (1 trial)

rifampin (2 trials)

sars-cov-2 rs (1 trial)

sofosbuvir (sovaldi) (1 trial)

trivalent p2vp8 subunit rotavirus vaccine (1 trial)

Drugs in Phase 1 Trials (7)

ch505tf gp120 (1 trial)

emtricitabine (emtriva) (1 trial)

gla-se (1 trial)

mf59 (1 trial)

rifabutin (mycobutin) (1 trial)

saavi dna-c2 vaccine (1 trial)

saavi mva-c vaccine (1 trial)

Drugs in Other Trials (6)

bifidobacterium animalis (1 trial)

bifidobacterium longum (1 trial)

maraviroc (selzentry) (1 trial)

misoprostol (cytotec) (1 trial)

nicotine (nicorette) (1 trial)

rabies vaccine (purified chick embryo cell vaccine) (RabAvert) (1 trial)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 58
  • # of Trial APIs: 80